Overview

A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

To investigate whether intraoperative intraportal chemotherapy combined with adjuvant chemotherapy as treatment could improve disease-free survival (DFS) in patients with curative colorectal cancer resection compared with adjuvant chemotherapy alone. This is a prospective, blind (doctors who done outcome measures were masked), multi-center, 2-arm randomized controlled trial.

Phase:

Phase 3

Details

Lead Sponsor:

Xu jianmin

Collaborators:

Ruijin Hospital
The Second Affiliated Hospital of Harbin Medical University
Zhejiang University

Treatments:

Floxuridine
Leucovorin
Levoleucovorin
Oxaliplatin